GWAS replication identifies PROC to be a novel candidate gene for childhood asthma

to patients in the ICU. Over the next five years there will be studies to optimize the use of these drugs and devices for specific indications (e.g. surfactants, aerosol antibiotics) and for specific applications such as high flow nasal delivery, delivery during noninvasive mechanical ventilation, and delivery to the intubated and mechanically ventilated patient. Large coordinated critical care research networks provide the ability to conduct well controlled clinical trials to determine the patient population, medications, dosage and duration of therapy, appropriate devices, and potential risks of these new therapies for the critically ill infant and child.